NASDAQ$TVTX
Travere Therapeutics Inc · Q3 2025 earnings
Q3 2025 earnings · · After market close · Investor relations
Briefing
Travere Therapeutics reported Q3 2025, revenue of $164.9M, net income of $25.7M, diluted EPS of $0.28.
For Q3 2025, Travere Therapeutics reported revenue of $164.9M, net income of $25.7M, diluted EPS was $0.28. The filing highlights segment trends, liquidity, and management commentary on the period.
- Revenue $164.9M.
- Net income $25.7M.
- Diluted EPS $0.28.
Headline financials
Revenue & EPS history
Travere · Revenue · Quarterly
$165M
Revenue by segment
Travere · $33.9M total across 2 segments · Q3 2023
- Tiopronin products$25.9M+2.0%76.3%
- FILSPARI$8.04M—23.7%
Forward guidance
Management discusses operating priorities, capital allocation, and sector-specific risks in the quarterly filing.
Tailwinds
- Headline results and segment commentary anchor the quarter.
- Balance sheet and liquidity support ongoing operations.
- Strategic initiatives cited in MD&A.
Headwinds
- Macro, rates, or input costs may pressure margins.
- One-time items can affect year-over-year comparability.
- Execution risk on guidance or restructuring plans.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2025
-0.6%
Avg return
Earnings day
-1.3%
Avg return
5 days after
-0.3%
Avg return
30 days after
49%
25 / 51 earnings
Positive
+16.6%
Q3 2025
Best reaction
-16.7%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.8% | -5.1% | +2.8% | |
| Q4 2025 | +3.1% | +0.1% | -8.4% | |
| Q3 2025 | +16.6% | +13.7% | +19.4% | |
| Q1 2025 | +1.6% | -2.6% | -27.6% | |
| Q4 2024 | -6.8% | -10.8% | -12.9% | |
| Q3 2024 | -1.1% | -0.0% | +5.9% | |
| Q2 2024 | -5.7% | -6.7% | -0.7% | |
| Q1 2024 | +7.8% | +0.6% | +25.1% | |
| Q4 2023 | -0.6% | +0.4% | -9.2% | |
| Q3 2023 | -4.7% | -16.0% | +30.3% | |
| Q2 2023 | -6.6% | -6.7% | -10.5% | |
| Q1 2023 | +5.6% | +4.2% | +19.7% | |
| Q4 2022 | +6.9% | +6.2% | +0.0% | |
| Q3 2022 | +3.1% | +0.5% | -12.4% | |
| Q2 2022 | +16.0% | +16.2% | +13.5% | |
| Q1 2022 | -14.2% | -13.2% | -6.4% | |
| Q4 2021 | +2.9% | +2.1% | -3.3% | |
| Q3 2021 | +10.0% | +15.1% | +10.8% | |
| Q2 2021 | -2.4% | +0.5% | +52.7% | |
| Q1 2021 | -16.6% | -17.4% | -41.2% | |
| Q4 2020 | -5.3% | -12.4% | -19.0% | |
| Q3 2020 | +1.6% | +11.4% | +18.1% | |
| Q2 2020 | -1.6% | -4.1% | -4.3% | |
| Q1 2020 | +7.6% | +0.8% | -0.9% | |
| Q4 2019 | -16.7% | -10.3% | -21.4% | |
| Q3 2019 | +4.4% | +8.0% | +20.7% | |
| Q2 2019 | -11.4% | -2.7% | -34.0% | |
| Q1 2019 | -7.9% | -5.5% | -2.7% | |
| Q4 2018 | +5.6% | +4.3% | +7.7% | |
| Q3 2018 | +0.6% | +1.2% | -4.4% | |
| Q2 2018 | -4.4% | -4.2% | +2.4% | |
| Q1 2018 | -5.2% | -5.7% | +11.6% | |
| Q4 2017 | +5.4% | +5.2% | -5.8% | |
| Q3 2017 | -13.4% | -16.3% | -17.1% | |
| Q2 2017 | -0.1% | +7.6% | +15.8% | |
| Q1 2017 | -4.4% | -6.5% | -7.1% | |
| Q4 2016 | +1.5% | -0.6% | -13.2% | |
| Q3 2016 | -4.3% | -1.2% | +8.5% | |
| Q2 2016 | +1.4% | -1.9% | -13.6% | |
| Q1 2016 | +5.2% | — | — | |
| Q4 2015 | -2.8% | — | — | |
| Q3 2015 | -10.0% | — | — | |
| Q2 2015 | +13.0% | — | — | |
| Q1 2015 | +5.8% | — | — | |
| Q4 2014 | +9.5% | — | — | |
| Q3 2014 | -14.4% | — | — | |
| Q2 2014 | -6.2% | — | — | |
| Q1 2014 | +4.9% | — | — | |
| Q4 2013 | +8.4% | — | — | |
| Q3 2013 | -5.8% | — | — | |
| Q2 2012 | -9.9% | — | — | |
| Q3 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro